Sanjivani Paranteral Ltd (SANJIVIN) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Sanjivani Paranteral Ltd reported strong Q4 and FY25 results, driven by new products and volume growth in existing products.
- Q4 FY25 revenue grew 41.3% YoY, with exports contributing 72.5% and injectables 71.9%.
- FY25 revenue grew 28.8% YoY, with exports at 81.5% and injectables at 58.7%.
- The company successfully completed regulatory audits and received approval for a Francophone African nation, opening doors to multiple French-speaking African countries.
- The Pune facility (SPL Infusion Private Limited) is operational, with commercial production starting soon and a robust 90-day order book.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.